secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2025-12-18T23:59:59+00:00
Accession:  0001193125-25-323802
Event type: debt
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 1.02, 2.03, 3.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical secures $175M debt facility, refinances MidCap loans; names lead independent director
--------------------------------------------------------------------------------

- Entered $175M senior secured loan: $60M term funded, $65M additional term (revenue-dependent), $50M revolver (expandable from $30M).
- Proceeds used to repay $50M term and $4M revolver from MidCap loans; paid $2.3M in prepayment/exit fees.
- Term loan at 1-month SOFR (floor 3%) + 5.05%; revolver at 3-month SOFR (floor 3%) + 4%; interest-only for 48 months.
- Post-refinancing liquidity ~$165M; dividends restricted under loan covenants.
- Board appointed John K. Bakewell as lead independent director; former CFO of Exact Sciences.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000119312525323802/0001193125-25-323802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000119312525323802/tmci-20251216.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-323802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer